Alderley Park – Redx (AIM:REDX), the clinical-stage biotechnology company focused on the discovery and development of novel, highly-targeted small molecule therapies for the treatment of cancer and fibrotic diseases, will present at Proactive One2One Virtual Investor Forum Thursday July 14, 2022. The webinar will start at 6:00 p.m. BST and investors can register here: https://www.proactiveinvestors.co.uk/register/event_details/403. Investors will also have the opportunity to ask questions during the event.
Lisa AnsonManaging Director of Redx, will provide an overview of the company following the recent successful fundraising of £34.3m and strong progress reported at the time of the company’s interim financial results in June. This included acceptance of the Investigational New Drug (IND) submission for JZP815, a pan-RAF inhibitor from the company’s partnership with Jazz Pharmaceutical. JZP815 is the fifth molecule in the Redx discovery engine to enter clinical development, underscoring the strength of Redx’s world-class medicinal chemistry expertise and drug discovery capabilities. The presentation will also include updates on the clinical programs for Redx’s wholly owned assets RXC004 and RXC007 and newly named development candidate RXC008.
Contact:
Redx Pharma Plc
UK Headquarter Caitlin Pearson
Communications Manager
E: ir@redxpharma.com
Lisa Anson
Chief executive officer
T: +44 (0)1625 469 918
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, highly-targeted small molecule therapies for the treatment of cancer and fibrotic diseases, initially aiming to advance them to clinical proof of concept before evaluating options for further development and potential value creation. Redx’s lead oncology product candidate, porcupine inhibitor RXC004, has entered a Phase 2 program in November 2021. The Company’s selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and has commenced a Phase 1 clinical trial in June 2021. Encouraging safety and pharmacokinetic data have been reported and a Phase 2 clinical program is confirmed to start in 2022. Redx’s third drug candidate, RXC008, a digestive tract-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease, is currently in the pre-IND phase, with phase 1 clinical studies to begin in 2023.
The Company has a solid track record in the discovery of new drug candidates thanks to its fundamental strengths in medicinal chemistry and translational science, allowing the Company to discover and develop differentiated therapies against biologically or clinically validated targets. The company’s achievements are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding portfolio, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), an inhibitor of BTK currently in phase 3 clinical development by Eli Lily following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), which Astra Zeneca is progressing in a Phase 1 clinical study. In addition, Redx has entered into collaborations with Jazz Pharmaceuticalwhich includes JZP815, a preclinical pan-RAF inhibitor, which has received IND clearance from the United States FDA and an early-stage oncology research collaboration.
(C) 2022 electronic news edition, source ENP Newswire
